You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Baxter
Boehringer Ingelheim
Harvard Business School
Dow

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

PLENAXIS Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Plenaxis patents expire, and what generic alternatives are available?

Plenaxis is a drug marketed by Speciality European and is included in one NDA.

The generic ingredient in PLENAXIS is abarelix. Additional details are available on the abarelix profile page.

Summary for PLENAXIS
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 29
Clinical Trials: 3
Patent Applications: 4,833
DailyMed Link:PLENAXIS at DailyMed
Drug patent expirations by year for PLENAXIS
Recent Clinical Trials for PLENAXIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PRAECIS Pharmaceuticals Inc.Phase 4
PRAECIS Pharmaceuticals Inc.Phase 2
Speciality European Pharma LimitedPhase 3

See all PLENAXIS clinical trials

Synonyms for PLENAXIS
(R)-N1-((S)-1-(((S)-1-((S)-2-(((R)-1-amino-1-oxopropan-2-yl)carbamoyl)pyrrolidin-1-yl)-6-(isopropylamino)-1-oxohexan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-2-((2S,5S,8R,11R,14R)-11-(4
183552-38-7
552A387
A12613
Abarelix
Abarelix (USAN/INN)
Abarelix [USAN:INN]
Abarelix [USAN]
Abarelix Acetate(Plenaxis)/
Abarelix-Depot-M
ABP000530
Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Nalpha-Me-Tyr]-D-Asn-Leu-ILys-Pro-DAla-NH2
AIWRTTMUVOZGPW-HSPKUQOVSA-N
BDBM50102442
C-23641
CC-23615
CHEBI:337298
CHEMBL1252
CS-5873
D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-
D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- 10
D02738
DB00106
DTXSID20171443
FT-0631200
GTPL1188
HY-13534
LS-181947
N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(sup 6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide
N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparagyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide
N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide
N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N(6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide
Plenaxis (TN)
Plenaxis depot
PPI 149
PPI-149
Q305555
R 3827
R-382
R-3827
SCHEMBL19712245
SCHEMBL9533
UNII-W486SJ5824
W486SJ5824

US Patents and Regulatory Information for PLENAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PLENAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for PLENAXIS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0794961 1190014-9 Sweden   Start Trial PRODUCT NAME: ABARELIX
0794961 C300484 Netherlands   Start Trial PRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922
0794961 CA 2011 00004 Denmark   Start Trial
0794961 11C0015 France   Start Trial PRODUCT NAME: ABARELIX, EVENTUELLEMENT SOUS FORME DE SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE IN FRANCE: 69026150 DU 20101126; REGISTRATION NO/DATE AT EEC: 57890.00.00 DU 20050922
0794961 CR 2011 00004 Denmark   Start Trial PRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922
0794961 SPC/GB11/006 United Kingdom   Start Trial PRODUCT NAME: ABARELIX, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE - 20050922; UK PL32828/001 20100917
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Baxter
Boehringer Ingelheim
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.